Ocular migraine and antiphospholipid antibodies--where we stand?
There is no doubt that ocular migraine also known as retinal migraine or ophthalmic migraine should not to be confused with ophthalmoplegic migraine. The hallmark of ocular migraine is the unilateral visual loss or "monocular transient loss of vision" associated or followed by the headache. Better safe than sorry, therefore an ophthalmologic examination during the migraine attack is the most diagnostic method. age with typical history for ocular migraine. Importantly supportive data sustain that different neuro-ophthalmologic manifestations as amaurosis fugax, retinal vascular thrombosis and optic neuropathy, may be considered as the ocular hallmarks of the Hughes's syndrome. Clues for the evaluating of antiphospholipid antibodies include recurrent thrombosis especially in young people, recurrent fetal loss, and thrombocytopenia. There are no studies that focus exclusively on the prophylaxis of ocular migraine. Ocular features due to antiphospholipid antibodies - induced thrombosis or Hughes's syndrome should be treated with anticoagulant therapy.
Department of Ohthalmology, Oradea University, Oradea, Romania. opticlar@gmail.com
Mihaela
M
Coroi
Ecaterina
E
Bontas
Rodica
R
Visan
Mladen
M
Defranceschi
Cristiana Daniela
CD
Cioranu
D020757:Amaurosis Fugax / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000276:immunology; D017152:Antibodies, Antiphospholipid / Q000097:blood*; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D015415:Biomarkers / Q000097:blood; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003937:Diagnosis, Differential; D006801:Humans; D008881:Migraine Disorders / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D012307:Risk Factors; D016896:Treatment Outcome
D017152:Antibodies, Antiphospholipid; D015415:Biomarkers; D002121:Calcium Channel Blockers